CN Patent

CN102438588B — 使用联合治疗法治疗疾病的方法

Assigned to Ambit Bioscience Corp · Expires 2015-04-01 · 11y expired

What this patent protects

本发明涉及一种在对象上治疗增殖性疾病的方法，包括给予对象治疗有效量的AC220和核苷类似物，拓扑异构酶抑制剂或蒽环类药物，或其组合物。

USPTO Abstract

本发明涉及一种在对象上治疗增殖性疾病的方法，包括给予对象治疗有效量的AC220和核苷类似物，拓扑异构酶抑制剂或蒽环类药物，或其组合物。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN102438588B
Jurisdiction: CN
Classification: —
Expires: 2015-04-01
Drug substance claim: No
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.